Overview
- 37 inspections across 35 sites are on record.
- 142 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-04-28.
At a glance
Inspections
37
Sites
35
Observations
142
Career since
Aug 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Mylan Pharmaceuticals Inc | 28 Apr 2026 | Human Drugs | |
| ChemPacific Corporation | 7 Apr 2026 | Human Drugs | On file |
| Pharmaceutics International, Inc. | 6 Mar 2026 | Human Drugs | View 483 → |
| MSD International GmbH (Singapore Branch) | 23 Jan 2026 | Human Drugs | On file |
| WES Pharma Inc. | 20 Nov 2025 | Human Drugs | View 483 → |
Sites inspected
Mylan Pharmaceuticals IncMorgantown, United States1 insp.
ChemPacific CorporationBaltimore, United States1 insp.
Pharmaceutics International, Inc.Cockeysville, United States1 insp.
MSD International GmbH (Singapore Branch)Singapore, Singapore1 insp.
WES Pharma Inc.Westminster, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Michael O Idowu5 shared
Catherine O Lamptey5 shared
Olumide A Akinyemi4 shared
Yaharn Su3 shared
Tanya R Syffrard2 shared
Claude Noel Y Zanetsie2 shared
Azeezat M Lawal2 shared
Paige R Mccoy2 shared
Khalid M Khan2 shared
Marcellinus D Dordunoo2 shared
Full investigator report
Get the verbatim findings behind Pushpa S Jayasekara's 142 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site